© 2026 Aqora Quantum S.A.S.

Terms Privacy Legal Notice

arXiv:2601.11413

Quantum-enhanced optimization for patient stratification in clinical trials

Laia Domingo, Christine Johnson

quant-phSubmitted Jan 16, 2026• Announced Jan 19, 2026• 0 citations

Abstract

Clinical trials are notorious for their high failure rates and steep costs, leading to wasted time and resources spend, prolonged development timelines, and delayed patient access to new therapies. A key contributor to these failures is biological uncertainty, which complicates trial design and weakens the ability to detect true treatment effects. In particular, inadequate patient stratification often results in covariate imbalances across treatment arms, masking treatment effects and reducing statistical power, even when therapies are effective for specific patient subpopulations. This work presents an optimization-based, quantum-enhanced approach to patient stratification that explicitly minimizes covariate imbalance across numerical and categorical variables, without altering protocol design or trial endpoints. Using real clinical trial data, we demonstrate that hybrid quantum-classical optimization methods achieve high-quality stratification while scaling efficiently to larger cohorts. In our benchmark study, the quantum-enhanced pipeline delivered over a 100x improvement in computational efficiency compared to classical approaches, enabling faster iteration and practical deployment at scale. This report shows how improved stratification can lead to decision-relevant gains, including up to a fivefold increase in statistical significance in treatment effect estimation, reducing treatment-effect dilution and increasing trial sensitivity. Together, these results show that optimization-driven stratification can strengthen clinical trial design, improve confidence in downstream decisions, and reduce the risk of costly late-stage failure.

Related papers

Clinical Trial Optimization via Quantum Computing for Drug Development

Kaan Karakas

Clinical trials represent one of the most resource-intensive and time-consuming phases of drug development, often constrained by complex patient stratification, high attrition rates, and logistical inefficiencies. Recent advances in quantum computing introduce new computational paradigms capable of addressing combinatorial optimization, probabilistic modeling, and high-dimensional data analysis challenges inherent in clinical research. This paper examines clinical trial optimization via quantum computing, exploring how quantum algorithms and hybrid quantum–classical frameworks can enhance patient recruitment, adaptive trial design, biomarker discovery, and outcome prediction. By synthesizing developments in quantum optimization, machine learning, and biomedical data analytics, the study evaluates the feasibility and potential impact of quantum-enabled methodologies in accelerating drug development pipelines. The findings suggest that quantum computing, when strategically integrated with classical infrastructures, may reduce development timelines, improve decision accuracy, and support more personalized and efficient clinical trial processes.

Next frontier.•Feb 7, 2026•0 citations

Entangling Oncology: Variational Quantum Eigensolver-Driven Optimization for Patient-Specific Multi-Modal Cancer Therapy Planning

Kelvin Chafachaipa, Richard Danda

Optimizing personalized cancer treatment plans that combine chemotherapy, radiation, and immunotherapy presents a complex challenge due to the need to balance efficacy with minimizing side effects across diverse patient profiles. This study introduces a novel hybrid quantum-classical framework leveraging the Variational Quantum Eigensolver (VQE) for multi-modal optimization. Treatment planning is formulated as a parameterized Hamiltonian, where the ground state corresponds to an optimal therapy regimen tailored to individual genomic and clinical data. The quantum VQE algorithm estimates ground state energy via quantum simulators, while classical optimizers iteratively refine circuit parameters. Benchmarking on synthetic datasets demonstrates that the hybrid approach enhances treatment personalization and computational efficiency over classical methods. Although current quantum hardware constraints limit immediate deployment, our findings validate the potential for quantum-enhanced optimization in clinical oncology. This research lays foundational groundwork for integrating near-term quantum algorithms into medical decision-making, with promising implications for improving cancer treatment outcomes and patient quality of life.

•Sep 1, 2025•1 citation

Towards quantum computing for clinical trial design and optimization: A perspective on new opportunities and challenges

Hakan Doğa, Sahin, M. Emre, Joao H. Bettencourt‐Silva +10 more

Clinical trials are pivotal in the drug discovery process to determine the safety and efficacy of a drug candidate. The high failure rates of these trials are attributed to deficiencies in clinical model development and protocol design. Improvements in the clinical drug design process could therefore yield significant benefits for all stakeholders involved. This paper examines the current challenges faced in clinical trial design and optimization, reviews established classical computational approaches, and introduces quantum algorithms aimed at enhancing these processes. Specifically, the focus is on three critical aspects: clinical trial simulations, site selection, and cohort identification. This study aims to provide a comprehensive framework that leverages quantum computing to innovate and refine the efficiency and effectiveness of clinical trials.

arXiv:2404.13113•Apr 19, 2024•1 citation

Quantum Computing for High-Dimensional Genomic Data Processing in Precision Medicine

Abhinav Pandey, Tameem Albassam, Kamal Sahib Mizal +3 more

High-quality processing and interpretation of large-scale genomic datasets in the high dimensionality required to reach treatment determinations within precision medicine hinges on discovered computational approaches, but computational approaches are often unsuccessful in processing information at this level, due to difficulties in processing high volumes of data coupled with noise and high dimensionality, usually becoming computationally slow and inconclusive throughout the process. We propose a new framework incorporating quantum computing to enable and enhance engagement with genomic data throughout clinically relevant scenarios. With the incorporation of existing quantum algorithms that facilitate dimensionality reduction, clustering, and classification, or proposed frameworks may improve disease biomarker detection and patient stratification capabilities. Our framework will incorporate a variety of quantum encoding methods and hybrid designs to minimize the classical limitations on these datasets, leading to a rapid clarification of the ontogeny of genomic datasets, and thus additionally providing the user with more clinically relevant data to interpret. Our results presented a significant increase in processing times and plausibility to clinical relevance, opening trajectories toward real-time, scalable, genomic diagnostics, providing a clear path toward confidence to broaden practice using quantum computing throughout precision medicine with genomic datasets as a basis for patient treatment.

Innovations in Machine, Engineering, and Digital Conference (IMED)•Mar 6, 2026•1 citation

The Role of Quantum Computing and AI in Enhancing Clinical Trial Matching Efficiency

Chandani Arora, Ramandeep Sandhu, Chander Prabha +3 more

Matching eligible patients to appropriate clinical trials remains a major challenge in healthcare due to large, heterogeneous datasets and complex eligibility criteria. This paper proposes a novel Quantum Machine Learning (QML) algorithm integrated with Natural Language Processing (NLP) techniques to optimize clinical trial matching. Unlike traditional methods, the proposed framework introduces a hybrid quantum–classical pseudocode workflow that combines quantum feature mapping with NLP-based data extraction to improve accuracy and efficiency in patient–trial matching. To strengthen the foundation of the proposed approach, key patented technologies, such as US20200005906A1 (intelligent patient–trial data matching) and US20220068443A1 (NLP-based eligibility interpretation), have been considered, demonstrating the growing feasibility of automated matching systems. The novelty of our work lies in unifying these advances within a scalable QML–NLP framework that reduces manual workload, shortens trial recruitment times, and improves overall research efficiency. By integrating quantum computing with NLP, this study moves beyond existing reviews and provides a concrete, implementable methodology to accelerate patient recruitment and advance personalized medicine.

Recent Patents on Engineering•Apr 7, 2026•0 citations

How can quantum computing be applied in clinical trial design and optimization?

Hakan Doğa, Aritra Bose, M. Emre Sahin +10 more

Clinical trials are necessary for assessing the safety and efficacy of treatments. However, trial timelines are severely delayed with minimal success due to a multitude of factors, including imperfect trial site selection, cohort recruitment challenges, lack of efficacy, absence of reliable biomarkers, etc. Each of these factors possesses a unique computational challenge, such as data management, trial simulations, statistical analyses, and trial optimization. Recent advancements in quantum computing offer a promising opportunity to overcome these hurdles. In this opinion we uniquely explore the application of quantum optimization and quantum machine learning (QML) to the design and execution of clinical trials. We examine the current capabilities and limitations of quantum computing and outline its potential to streamline clinical trials.

Trends in Pharmacological Sciences•Sep 23, 2024•41 citations

Clinical trials are notorious for their high failure rates and steep costs, leading to wasted time and resources spend, prolonged development timelines, and delayed patient access to new therapies. A key contributor to these failures is biological uncertainty, which complicates trial design and weakens the ability to detect true treatment effects. In particular, inadequate patient stratification often results in covariate imbalances across treatment arms, masking treatment effects and reducing statistical power, even when therapies are effective for specific patient subpopulations. This work presents an optimization-based, quantum-enhanced approach to patient stratification that explicitly minimizes covariate imbalance across numerical and categorical variables, without altering protocol design or trial endpoints. Using real clinical trial data, we demonstrate that hybrid quantum-classical optimization methods achieve high-quality stratification while scaling efficiently to larger cohorts. In our benchmark study, the quantum-enhanced pipeline delivered over a 100x improvement in computational efficiency compared to classical approaches, enabling faster iteration and practical deployment at scale. This report shows how improved stratification can lead to decision-relevant gains, including up to a fivefold increase in statistical significance in treatment effect estimation, reducing treatment-effect dilution and increasing trial sensitivity. Together, these results show that optimization-driven stratification can strengthen clinical trial design, improve confidence in downstream decisions, and reduce the risk of costly late-stage failure.

Clinical trials represent one of the most resource-intensive and time-consuming phases of drug development, often constrained by complex patient stratification, high attrition rates, and logistical inefficiencies. Recent advances in quantum computing introduce new computational paradigms capable of addressing combinatorial optimization, probabilistic modeling, and high-dimensional data analysis challenges inherent in clinical research. This paper examines clinical trial optimization via quantum computing, exploring how quantum algorithms and hybrid quantum–classical frameworks can enhance patient recruitment, adaptive trial design, biomarker discovery, and outcome prediction. By synthesizing developments in quantum optimization, machine learning, and biomedical data analytics, the study evaluates the feasibility and potential impact of quantum-enabled methodologies in accelerating drug development pipelines. The findings suggest that quantum computing, when strategically integrated with classical infrastructures, may reduce development timelines, improve decision accuracy, and support more personalized and efficient clinical trial processes.

Optimizing personalized cancer treatment plans that combine chemotherapy, radiation, and immunotherapy presents a complex challenge due to the need to balance efficacy with minimizing side effects across diverse patient profiles. This study introduces a novel hybrid quantum-classical framework leveraging the Variational Quantum Eigensolver (VQE) for multi-modal optimization. Treatment planning is formulated as a parameterized Hamiltonian, where the ground state corresponds to an optimal therapy regimen tailored to individual genomic and clinical data. The quantum VQE algorithm estimates ground state energy via quantum simulators, while classical optimizers iteratively refine circuit parameters. Benchmarking on synthetic datasets demonstrates that the hybrid approach enhances treatment personalization and computational efficiency over classical methods. Although current quantum hardware constraints limit immediate deployment, our findings validate the potential for quantum-enhanced optimization in clinical oncology. This research lays foundational groundwork for integrating near-term quantum algorithms into medical decision-making, with promising implications for improving cancer treatment outcomes and patient quality of life.

Clinical trials are pivotal in the drug discovery process to determine the safety and efficacy of a drug candidate. The high failure rates of these trials are attributed to deficiencies in clinical model development and protocol design. Improvements in the clinical drug design process could therefore yield significant benefits for all stakeholders involved. This paper examines the current challenges faced in clinical trial design and optimization, reviews established classical computational approaches, and introduces quantum algorithms aimed at enhancing these processes. Specifically, the focus is on three critical aspects: clinical trial simulations, site selection, and cohort identification. This study aims to provide a comprehensive framework that leverages quantum computing to innovate and refine the efficiency and effectiveness of clinical trials.

High-quality processing and interpretation of large-scale genomic datasets in the high dimensionality required to reach treatment determinations within precision medicine hinges on discovered computational approaches, but computational approaches are often unsuccessful in processing information at this level, due to difficulties in processing high volumes of data coupled with noise and high dimensionality, usually becoming computationally slow and inconclusive throughout the process. We propose a new framework incorporating quantum computing to enable and enhance engagement with genomic data throughout clinically relevant scenarios. With the incorporation of existing quantum algorithms that facilitate dimensionality reduction, clustering, and classification, or proposed frameworks may improve disease biomarker detection and patient stratification capabilities. Our framework will incorporate a variety of quantum encoding methods and hybrid designs to minimize the classical limitations on these datasets, leading to a rapid clarification of the ontogeny of genomic datasets, and thus additionally providing the user with more clinically relevant data to interpret. Our results presented a significant increase in processing times and plausibility to clinical relevance, opening trajectories toward real-time, scalable, genomic diagnostics, providing a clear path toward confidence to broaden practice using quantum computing throughout precision medicine with genomic datasets as a basis for patient treatment.

Matching eligible patients to appropriate clinical trials remains a major challenge in healthcare due to large, heterogeneous datasets and complex eligibility criteria. This paper proposes a novel Quantum Machine Learning (QML) algorithm integrated with Natural Language Processing (NLP) techniques to optimize clinical trial matching. Unlike traditional methods, the proposed framework introduces a hybrid quantum–classical pseudocode workflow that combines quantum feature mapping with NLP-based data extraction to improve accuracy and efficiency in patient–trial matching. To strengthen the foundation of the proposed approach, key patented technologies, such as US20200005906A1 (intelligent patient–trial data matching) and US20220068443A1 (NLP-based eligibility interpretation), have been considered, demonstrating the growing feasibility of automated matching systems. The novelty of our work lies in unifying these advances within a scalable QML–NLP framework that reduces manual workload, shortens trial recruitment times, and improves overall research efficiency. By integrating quantum computing with NLP, this study moves beyond existing reviews and provides a concrete, implementable methodology to accelerate patient recruitment and advance personalized medicine.

Clinical trials are necessary for assessing the safety and efficacy of treatments. However, trial timelines are severely delayed with minimal success due to a multitude of factors, including imperfect trial site selection, cohort recruitment challenges, lack of efficacy, absence of reliable biomarkers, etc. Each of these factors possesses a unique computational challenge, such as data management, trial simulations, statistical analyses, and trial optimization. Recent advancements in quantum computing offer a promising opportunity to overcome these hurdles. In this opinion we uniquely explore the application of quantum optimization and quantum machine learning (QML) to the design and execution of clinical trials. We examine the current capabilities and limitations of quantum computing and outline its potential to streamline clinical trials.